GLP-1 receptor agonist

Dulaglutide

The Trulicity label gives dulaglutide's elimination half-life as approximately 5 days and the EU product information gives 4.7 days; the app lists 108 hours, about 4.5 days.1,2

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Dulaglutide after one dose: 50% at ~108 h, 25% at 216 h, 12.5% at 324 h.

Drawn from the half-life in the app's model, ~108 h. The model's figures

Dulaglutide is a GLP-1 receptor agonist made by Eli Lilly and Company and sold in the United States as Trulicity.1 The US label gives 2014 as the initial approval year, and the European product information gives 21 November 2014 as the date of first authorisation.1,2 The label lists two uses: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.1 The label carries a boxed warning: in male and female rats dulaglutide caused a dose-related and treatment-duration-dependent increase in thyroid C-cell tumors, and it is unknown whether it causes these tumors, including medullary thyroid carcinoma, in humans.1 The app grades the evidence for dulaglutide as strong. The pivotal trials described below were funded by Eli Lilly and Company, apart from SUSTAIN 7, which Novo Nordisk funded.5,7,8,11

The label describes dulaglutide as a fusion protein of two identical, disulfide-linked chains, each with an N-terminal GLP-1 analog sequence linked by a small peptide linker to the Fc portion of a modified human immunoglobulin G4 heavy chain, with an overall molecular weight of approximately 63 kilodaltons.1 The GLP-1 analog portion is 90% homologous to native human GLP-1 (7-37), with structural modifications in the part that interacts with the enzyme dipeptidyl-peptidase-IV (DPP-4).1 The European product information adds that, unlike native GLP-1, dulaglutide is resistant to DPP-4 degradation and has a large size that slows absorption and reduces renal clearance.2 According to the label, dulaglutide activates the GLP-1 receptor on pancreatic beta cells, raising intracellular cyclic AMP and leading to glucose-dependent insulin release; it also decreases glucagon secretion and slows gastric emptying.1 In a monotherapy trial described on the label, once-weekly 0.75 mg and 1.5 mg increased fasting insulin at week 26 by 35.38 and 17.50 pmol/L and lowered fasting glucagon by 1.71 and 2.05 pmol/L.1 The label states that the delay in gastric emptying is dose-dependent but is attenuated with the label's stepwise escalation to higher doses, is largest after the first dose and diminishes with subsequent doses, and that it has the potential to reduce the rate of absorption of concomitantly administered oral medications.1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~108 h
Bioavailability
65%
Typical dose
0.75–4.5 mg/week
Route
SubQ
Time to peak
~48 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics6 rows
ParameterApp's figureReported in the sources
Half-life~108 h (4.5 days)Elimination half-life of approximately 5 days on the US label and in the European product information (4.7 days in its pharmacology section); terminal elimination half-life of 5 days in a Lilly pharmacokinetic analysis; geometric mean half-life of 4 to 5 days in a Chinese phase 1 study1,2,3,4
Time to peak~48 hSteady-state time to maximum concentration of 24 to 72 hours with a median of 48 hours on the label; 48 hours in the European product information, in Geiser and colleagues and in the Chinese phase 1 study1,2,3,4
Bioavailability65%Mean absolute bioavailability after single subcutaneous doses of 65% at 0.75 mg and 47% at 1.5 mg; for 3 mg and 4.5 mg it is estimated to be similar to 1.5 mg, "although this has not been specifically studied"1,2
ModelOne-compartmentPopulation pharmacokinetics "well described by a two-compartment model with first-order absorption and elimination" in Geiser and colleagues; the label gives an apparent central volume of 3.09 L and peripheral volume of 5.98 L3,1
ClearanceNot listedApparent population mean clearance of 0.142 L/h on the label; 0.126 L/h in Geiser and colleagues1,3
Steady stateNot listedReached between 2 and 4 weeks of once-weekly dosing, with an accumulation ratio of approximately 1.56 on the label1

Geiser and colleagues (Eli Lilly and Company, Clinical Pharmacokinetics, 2016) pooled clinical pharmacology and phase 2 and 3 data; all seven authors list Eli Lilly and Company as their affiliation.3 They report no pharmacokinetic difference between arm, thigh or abdomen injection sites.3 The label states that pharmacokinetics are similar between healthy subjects and people with type 2 diabetes mellitus, and that age (65 years or older), sex, race, ethnicity, body weight, and renal or hepatic impairment did not have a clinically relevant effect.1

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: once weekly1.

An illustration from a pharmacokinetic model using a half-life of 108 hours (4.5 days). It is not a measured level or a suggested dose.

4

Human studies

Table 4.1Human studies4 rows
Study and yearDesignPeopleDose and lengthMain result
Gerstein and colleagues, REWIND, Lancet 20195Randomised, double-blind, placebo-controlled; funded by Eli Lilly and Company59901 people aged at least 50 with type 2 diabetes and a previous cardiovascular event or cardiovascular risk factors5Dulaglutide 1.5 mg or placebo weekly by subcutaneous injection; median follow-up 5.4 years5First occurrence of non-fatal myocardial infarction, non-fatal stroke or death from cardiovascular causes: 594 (12.0%) against 663 (13.4%), hazard ratio 0.88 (95% CI 0.79 to 0.99; p=0.026); all-cause mortality did not differ (HR 0.90, 95% CI 0.80 to 1.01; p=0.067); gastrointestinal adverse events 47.4% against 34.1%5
Nauck and colleagues, AWARD-5, Diabetes Care 20147Multicentre, adaptive, double-blind, parallel-arm; sponsored by Eli Lilly and Company71,098 metformin-treated adults with type 2 diabetes, mean HbA1c 8.1%7Dulaglutide 1.5 mg, dulaglutide 0.75 mg, sitagliptin 100 mg or placebo (placebo to 26 weeks); primary end point 52 weeks7HbA1c change at 52 weeks -1.10%, -0.87% and -0.39% (least squares mean); both dulaglutide doses superior to sitagliptin; no severe hypoglycemia; discontinuation for adverse events 10.9%, 7.6% and 9.5%7
AWARD-11, ClinicalTrials.gov NCT03495102 and Bonora and colleagues, Diabetes, Obesity and Metabolism 20218,9Randomised, double-blind, parallel-arm phase 3; sponsored by Eli Lilly and Company8,91842 adults with type 2 diabetes inadequately controlled on metformin; mean age 57.1 years, HbA1c 8.6%8,9Dulaglutide 1.5, 3.0 or 4.5 mg weekly added to metformin; primary end point week 36, trial to 52 weeks8,9HbA1c change at week 36: -1.53%, -1.71% and -1.87%; differences against 1.5 mg of -0.17 (95% CI -0.29 to -0.06) and -0.34 (95% CI -0.45 to -0.22); weight -3.1, -4.0 and -4.7 kg8,9
Pratley and colleagues, SUSTAIN 7, Lancet Diabetes and Endocrinology 201811Randomised, open-label phase 3b; funded by Novo Nordisk111201 adults with type 2 diabetes and HbA1c 7.0 to 10.5% on metformin monotherapy11Semaglutide 0.5 or 1.0 mg against dulaglutide 0.75 or 1.5 mg weekly; 40 weeks11HbA1c fell by 1.5 (semaglutide 0.5 mg) against 1.1 (dulaglutide 0.75 mg) and by 1.8 against 1.4 points (1.0 mg against 1.5 mg); weight fell by 4.6 against 2.3 kg and 6.5 against 3.0 kg11

Deeper analysis: REWIND

Gerstein and colleagues, from the Population Health Research Institute at McMaster University and Hamilton Health Sciences, reported REWIND in The Lancet in 2019.5 The trial enrolled 9901 people between August 2011 and August 2013 at 371 sites in 24 countries and randomly assigned 4949 to dulaglutide and 4952 to placebo.5 The label adds that 31.5% of randomized patients had established cardiovascular disease and 62.8% had multiple cardiovascular risk factors without established disease.1 The primary outcome was the first occurrence of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (including unknown causes), assessed in the intention-to-treat population.5 It occurred at 2.4 per 100 person-years on dulaglutide and 2.7 on placebo, a hazard ratio of 0.88 (95% CI 0.79 to 0.99; p=0.026).5 The label's component table lists cardiovascular death at a hazard ratio of 0.91 (0.78, 1.06), non-fatal myocardial infarction at 0.96 (0.79, 1.16) and non-fatal stroke at 0.76 (0.61, 0.95), and describes the components as listed descriptively for supportive purposes.1 All-cause mortality "did not differ between groups": 536 (10.8%) on dulaglutide and 592 (12.0%) on placebo (HR 0.90, 95% CI 0.80 to 1.01; p=0.067).5 Gastrointestinal adverse events were reported by 2347 (47.4%) people on dulaglutide and 1687 (34.1%) on placebo (p<0.0001).5 The registry entry lists serious adverse events in 1991 of 4943 people on dulaglutide and 2044 of 4949 on placebo, and deaths in 536 and 592.6 The label reports diabetic retinopathy complications in 1.9% on dulaglutide and 1.5% on placebo, 8.5% against 6.2% among those with a history of retinopathy, and one case of C-cell hyperplasia with elevated calcitonin levels after treatment.1 The funder was Eli Lilly and Company, and three authors (Lakshmanan, Riesmeyer and Atisso) list Eli Lilly and Company, Indianapolis, as their affiliation; the registry names the company as lead sponsor.5,6 The authors write that dulaglutide "could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors".5 The authors' own limitations are not quoted here because the paper's text was not available beyond its summary record.

Deeper analysis: AWARD-11 (dulaglutide 3.0 and 4.5 mg)

AWARD-11 tested higher dulaglutide doses against 1.5 mg in 1842 adults with type 2 diabetes added to metformin; the registry lists Eli Lilly and Company as lead sponsor, and the label describes the double-blind, 1:1:1 randomisation.8,1 According to the post hoc gastrointestinal analysis, patients started on 0.75 mg for 4 weeks before escalating stepwise every 4 weeks until the randomised dose was reached.10 The registry's primary outcome was the change in HbA1c from baseline to week 36; least squares mean changes were -1.53, -1.71 and -1.87 percentage points for 1.5, 3 and 4.5 mg (standard error 0.04 in each group).8 The difference against 1.5 mg was -0.17 (95% CI -0.29 to -0.06; P 0.003) for 3 mg and -0.34 (95% CI -0.45 to -0.22) for 4.5 mg.8 Bonora and colleagues (Diabetes, Obesity and Metabolism, 2021) report that at 36 weeks "dulaglutide 3.0 and 4.5 mg were superior to 1.5 mg for weight change from baseline", with changes of -3.1, -4.0 and -4.7 kg.9 The authors state that the population was patients with chronic hyperglycaemia who required intensification of antihyperglycaemic therapy, so "the results may not be generalizable to patients who do not meet these criteria"; they also state that other than the weight analysis at the primary 36-week time point, the endpoints and analyses in the report "were defined in the protocol as exploratory", and that the subgroup analyses, all but one prespecified, "are still considered exploratory".9 Registry safety counts to week 56 were 3 deaths among 612 on 1.5 mg, 4 among 616 on 3 mg and 4 among 614 on 4.5 mg, with serious adverse events in 53, 45 and 38 people.8 Van and colleagues (Diabetes Therapy, 2021, funded by Eli Lilly and Company) reported in a post hoc analysis that nausea (up to 8%), vomiting (up to 2%) and diarrhea (up to 4%) were highest soon after starting 0.75 mg, that severe events occurred in up to 0.6% of patients, and that discontinuation due to nausea was up to 1.5% across groups.10 Those authors note that "This clinical trial dose escalation scheme may not necessarily reflect routine clinical care situations" and that excluding events with no stop date "may underestimate the overall incidence".10 In the Bonora paper, REM, RM, MAB, AYMK and DAC are described as employees of Eli Lilly and Company who own stock in the company, and the trial was sponsored by Eli Lilly and Company.9

Deeper analysis: AWARD-5

Nauck and colleagues reported AWARD-5 in Diabetes Care in 2014 as a multicentre, adaptive, double-blind, parallel-arm study in metformin-treated adults with type 2 diabetes.7 Its first part selected doses, with 230 patients adaptively randomised, and dulaglutide 1.5 mg and 0.75 mg were chosen for further assessment.7 At 52 weeks HbA1c changed by -1.10 (1.5 mg), -0.87 (0.75 mg) and -0.39 (sitagliptin) percentage points, and weight by -3.03, -2.60 and -1.53 kg.7 Discontinuation for adverse events was similar across arms (33 [10.9%], 23 [7.6%] and 30 [9.5%]), and discontinuation because of nausea "was only reported with dulaglutide" (8 [2.6%] at 1.5 mg and 3 [1.0%] at 0.75 mg).7 Total hypoglycemia at 52 weeks was 10.2%, 5.3% and 4.8% in the three arms, with no severe events, and the authors report no cases of pancreatitis with dulaglutide and anti-drug antibodies in 1.3%.7 The study was sponsored by Eli Lilly and Company, and Z.S. and Z.M. are described as employees of the company.7 The disclosure statement also says M.N. received research grants from Eli Lilly and Company among other companies, and R.S.W. participated in multicenter clinical trials sponsored by Eli Lilly and Company among others.7 The text read contains no separate limitations paragraph, but the authors flag one caveat about a beta-cell function comparison: "HOMA2 assesses β-cell function in the fasting state when dulaglutide levels were continuously elevated".7

Deeper analysis: SUSTAIN 7 (semaglutide against dulaglutide)

Pratley and colleagues reported SUSTAIN 7 in The Lancet Diabetes and Endocrinology in 2018 as an open-label phase 3b trial in 1201 adults on metformin monotherapy, funded by Novo Nordisk.11 Two authors (Andreassen and Navarria) list Novo Nordisk, Søborg, Denmark, as their affiliation.11 The dulaglutide arms were 0.75 mg and 1.5 mg, compared with semaglutide 0.5 mg and 1.0 mg respectively; HbA1c fell by 1.5 against 1.1 points (estimated treatment difference -0.40, 95% CI -0.55 to -0.25) and by 1.8 against 1.4 points (-0.41, 95% CI -0.57 to -0.25).11 Weight fell by 4.6 kg against 2.3 kg (ETD -2.26 kg, -3.02 to -1.51) and by 6.5 kg against 3.0 kg (ETD -3.55 kg, -4.32 to -2.78).11 Gastrointestinal disorders occurred in 100 (33%) of 299 on dulaglutide 0.75 mg and 143 (48%) of 299 on 1.5 mg, against 43% and 44% on the two semaglutide doses, and were also the most common reason for discontinuing treatment with semaglutide and dulaglutide; 72 (6%) of the 1201 patients withdrew from the trial (13 on dulaglutide 0.75 mg and 16 on dulaglutide 1.5 mg), and there were six fatalities, one in each semaglutide group and two in each dulaglutide group.11 The authors conclude that semaglutide "was superior to dulaglutide in improving glycaemic control and reducing bodyweight" at both doses, "with a similar safety profile".11 The authors' limitations are not quoted because the source text covers only the summary record.

5

Doses reported in studies and on labels

Table 5.1Doses reported in studies and on labels6 rows
Source and settingDose and routeComparator, n and lengthReported dosing
US label, adults with type 2 diabetes1Subcutaneous, once weeklyLabel textStarting dosage 0.75 mg; may be increased to 1.5 mg after 4 weeks; further increases in 1.5 mg steps after at least 4 weeks on the current dosage; maximum 4.5 mg weekly1
US label, pediatric patients 10 years and older1Subcutaneous, once weeklyLabel textStarting dosage 0.75 mg; a step to 1.5 mg once weekly after at least 4 weeks on 0.75 mg1
REWIND51.5 mg weekly, subcutaneousPlacebo; 9901 people; median follow-up 5.4 yearsCardiovascular outcomes trial5
AWARD-571.5 mg or 0.75 mg weeklySitagliptin 100 mg and placebo; N = 1,098; 52 weeks to primary end pointAdded to metformin7
AWARD-118,9,101.5, 3.0 or 4.5 mg weekly, subcutaneousEach dose against 1.5 mg; n = 612, 616, 614; primary end point week 36, trial 52 weeksStarted on 0.75 mg for 4 weeks, then stepwise every 4 weeks to the randomised dose10,9
SUSTAIN 711Dulaglutide 0.75 mg or 1.5 mg weekly, subcutaneousSemaglutide 0.5 or 1.0 mg; 1201 randomised; 40 weeksOpen-label11
6

Side effects reported

Sources in this part

  1. 1Eli Lilly and Company, 2026

The label lists nausea, diarrhea, vomiting, abdominal pain and decreased appetite as the most common adverse reactions (incidence of 5% or more).1 In the label's pool of placebo-controlled trials (1,670 adults on dulaglutide), gastrointestinal reactions occurred in 21% on placebo, 32% on 0.75 mg and 41% on 1.5 mg.1 Discontinuation due to gastrointestinal reactions was 1.3% on 0.75 mg and 3.5% on 1.5 mg against 0.2% on placebo, and severe gastrointestinal reactions were reported in 2.2% and 4.3% against 1.4%.1 For the 3 mg and 4.5 mg doses the label states that the adverse reaction profile in the 1842-patient trial "is consistent with previous clinical trials in adults".1 Acute pancreatitis, "including fatal and non-fatal hemorrhagic or necrotizing pancreatitis", has been observed with GLP-1 receptor agonists including Trulicity.1 In the label's pooled registration studies, 12 pancreatitis-related adverse reactions (3.4 cases per 1,000 patient years) were reported in patients exposed to dulaglutide against 3 (2.7 cases per 1000 patient years) on non-incretin comparators, and adjudicated pancreatitis was confirmed in 5 patients exposed to dulaglutide (1.4 per 1,000 patient years) and 1 on non-incretin comparators (0.88 per 1,000 patient years); in the 3 mg and 4.5 mg trial it occurred in 1 patient on 1.5 mg (0.2%), 2 on 3 mg (0.3%) and 3 on 4.5 mg (0.5%).1 The label states that use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia.1 Postmarketing reports include serious hypersensitivity reactions (anaphylactic reactions and angioedema) and acute kidney injury, the latter mostly in people with gastrointestinal reactions leading to dehydration.1 The label also lists acute gallbladder disease and rare postmarketing reports of pulmonary aspiration in people on GLP-1 receptor agonists who underwent elective surgery or procedures requiring general anesthesia or deep sedation.1 Contraindications are a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a serious hypersensitivity reaction to dulaglutide or any product component.1 One case of medullary thyroid carcinoma was reported in a person on dulaglutide in a clinical trial, who had pretreatment calcitonin levels approximately 8 times the upper limit of normal.1

The app lists HbA1c and fasting glucose as the markers to monitor for dulaglutide. HbA1c was the primary outcome in AWARD-5, AWARD-11 and SUSTAIN 7, as described above.7,8,11 Fasting glucose improved early: AWARD-5 reports an early improvement after 2 weeks, and the Chinese phase 1 study reports significant reductions in baseline-corrected fasting glucose and HbA1c in patients on 0.75 mg and 1.5 mg.7,4 The label states that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of medullary thyroid carcinoma.1 The label calls for renal function monitoring in people reporting volume-depleting reactions.1 In AWARD-5, the authors report increases within the normal range in median values of pancreatic enzymes with dulaglutide and sitagliptin that were similar in magnitude to the changes reported with liraglutide, and note that "there were no observed clinical consequences of these findings".7

The FDA label gives 2014 as the initial US approval year, and the European product information gives 21 November 2014 as the date of first authorisation.1,2 A text search of the extracted 2026 WADA Prohibited List returned no match for dulaglutide, semaglutide, liraglutide or exenatide.12 The list's class S2 on peptide hormones, growth factors, related substances and mimetics gives examples such as growth hormone fragments, growth hormone releasing factors and gonadotrophins, and none of its listed examples is a GLP-1 receptor agonist.12

9

Storage and handling

Sources in this part

  1. 1Eli Lilly and Company, 2026

The label states that Trulicity is stored in a refrigerator at 36°F to 46°F (2°C to 8°C).1 It also states that, if needed, each single-dose pen can be kept at room temperature not exceeding 86°F (30°C) for a total of 14 days.1

10

What is not known

Sources in this part

  1. 1Eli Lilly and Company, 2026

The label states that it is unknown whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent findings has not been determined.1 The label says absolute bioavailability for the 3 mg and 4.5 mg doses was estimated and "has not been specifically studied".1 The label reports limited experience with concomitant medications at 3 mg and 4.5 mg.1 The app lists an absorption half-life of 50 hours; the label, the European product information and the two pharmacokinetic papers read do not state a matching absorption half-life. A PubMed query for dulaglutide against semaglutide or liraglutide matched 128 records, of which 20 were listed; among those 20, SUSTAIN 7 was the randomised comparison with semaglutide, and its dulaglutide arms were 0.75 mg and 1.5 mg.

What is the half-life of dulaglutide?

The Trulicity label gives dulaglutide's elimination half-life as approximately 5 days, and the app lists about 4.5 days (108 hours).1 The European product information gives 4.7 days in its pharmacology section, and a Chinese phase 1 study reported a geometric mean half-life of 4 to 5 days.2,4

How long does dulaglutide take to reach its peak level?

The label gives a steady-state time to maximum concentration of 24 to 72 hours with a median of 48 hours, and the app lists about 48 hours.1

What is the bioavailability of dulaglutide?

The label gives a mean absolute bioavailability of 65% after a single 0.75 mg subcutaneous dose and 47% after a single 1.5 mg dose, and the app lists 65%.1

Is dulaglutide banned by WADA?

Dulaglutide is not named in the extracted text of the WADA 2026 Prohibited List, which returned no match in a text search.12

Does dulaglutide reduce cardiovascular events?

In REWIND (9901 people with type 2 diabetes, median follow-up 5.4 years), the primary composite of non-fatal myocardial infarction, non-fatal stroke or death from cardiovascular causes occurred in 12.0% on dulaglutide 1.5 mg and 13.4% on placebo, a hazard ratio of 0.88 (95% CI 0.79 to 0.99).5 All-cause mortality did not differ between groups, and the trial was funded by Eli Lilly and Company.5

What are the most common side effects of dulaglutide?

The label lists nausea, diarrhea, vomiting, abdominal pain and decreased appetite as the most common adverse reactions, each with an incidence of 5% or more.1 In REWIND, 47.4% on dulaglutide and 34.1% on placebo reported a gastrointestinal adverse event.5

Does dulaglutide carry a boxed warning?

The label carries a boxed warning for the risk of thyroid C-cell tumors.1 It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.1

How does dulaglutide compare with semaglutide in trials?

In SUSTAIN 7, funded by Novo Nordisk, semaglutide 1.0 mg lowered weight by 6.5 kg against 3.0 kg for dulaglutide 1.5 mg, and the authors report semaglutide as superior for HbA1c and bodyweight.11

13

References

  1. Eli Lilly and Company. Trulicity (dulaglutide) injection, for subcutaneous use. US prescribing information, DailyMed version 62, 2026. DailyMed label
  2. European Medicines Agency. Trulicity: summary of product characteristics (EPAR product information). EMA product information
  3. Geiser JS, et al. Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Clin Pharmacokinet 2016. PMID 26507721
  4. Xu J, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study. Adv Ther 2022. PMID 34787823
  5. Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019. PMID 31189511
  6. ClinicalTrials.gov. NCT01394952. Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND). NCT01394952
  7. Nauck M, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014. PMID 24742660
  8. ClinicalTrials.gov. NCT03495102. A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (AWARD-11). NCT03495102
  9. Bonora E, et al. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11. Diabetes Obes Metab 2021. PMID 34189841
  10. Van J, et al. Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11. Diabetes Ther 2021. PMID 34514554
  11. Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018. PMID 29397376
  12. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list